Cargando…

Tianlongkechuanling Inhibits Pulmonary Fibrosis Through Down-Regulation of Arginase-Ornithine Pathway

Background: Pulmonary Fibrosis (PF) is an interstitial lung disease characterized by excessive accumulation of extracellular matrix in the lungs, which disrupts the structure and gas exchange of the alveoli. There are only two approved therapies for PF, nintedanib (Nib) and pirfenidone. Therefore, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lili, Qu, Sihao, Wang, Lu, Wang, Chunguo, Yu, Qinghe, Zhang, Zhimin, Diao, Yirui, Zhang, Binbin, Li, Yadong, Shi, Yuanyuan, Wang, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114272/
https://www.ncbi.nlm.nih.gov/pubmed/33995084
http://dx.doi.org/10.3389/fphar.2021.661129
_version_ 1783691027860684800
author Zhang, Lili
Qu, Sihao
Wang, Lu
Wang, Chunguo
Yu, Qinghe
Zhang, Zhimin
Diao, Yirui
Zhang, Binbin
Li, Yadong
Shi, Yuanyuan
Wang, Peng
author_facet Zhang, Lili
Qu, Sihao
Wang, Lu
Wang, Chunguo
Yu, Qinghe
Zhang, Zhimin
Diao, Yirui
Zhang, Binbin
Li, Yadong
Shi, Yuanyuan
Wang, Peng
author_sort Zhang, Lili
collection PubMed
description Background: Pulmonary Fibrosis (PF) is an interstitial lung disease characterized by excessive accumulation of extracellular matrix in the lungs, which disrupts the structure and gas exchange of the alveoli. There are only two approved therapies for PF, nintedanib (Nib) and pirfenidone. Therefore, the use of Chinese medicine for PF is attracting attention. Tianlongkechuanling (TL) is an effective Chinese formula that has been applied clinically to alleviate PF, which can enhance lung function and quality of life. Purpose: The potential effects and specific mechanisms of TL have not been fully explored, yet. In the present study, proteomics was performed to explore the therapeutic protein targets of TL on Bleomycin (BLM)-induced Pulmonary Fibrosis. Method: BLM-induced PF mice models were established. Hematoxylineosin staining and Masson staining were used to analyze histopathological changes and collagen deposition. To screen the differential proteins expression between the Control, BLM, BLM + TL and BLM + Nib (BLM + nintedanib) groups, quantitative proteomics was performed using tandem mass tag (TMT) labeling with nanoLC-MS/MS [nano liquid chromatographymass spectrometry]). Changes in the profiles of the expressed proteins were analyzed using the bioinformatics tools Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG). The protein–protein interactions (PPI) were established by STRING. Expressions of α-smooth muscle actin (α-SMA), Collagen I (Col1a1), Fibronectin (Fn1) and enzymes in arginase-ornithine pathway were detected by Western blot or RT-PCR. Result: TL treatments significantly ameliorated BLM-induced collagen deposition in lung tissues. Moreover, TL can inhibit the protein expressions of α-SMA and the mRNA expressions of Col1a1 and Fn1. Using TMT technology, we observed 253 differentially expressed proteins related to PPI networks and involved different KEGG pathways. Arginase-ornithine pathway is highly significant. The expression of arginase1 (Arg1), carbamoyltransferase (OTC), carbamoy-phosphate synthase (CPS1), argininosuccinate synthase (ASS1), ornithine aminotransferase (OAT) argininosuccinate lyase (ASL) and inducible nitric oxide synthase (iNOS) was significantly decreased after TL treatments. Conclusion: Administration of TL in BLM-induced mice resulted in decreasing pulmonary fibrosis. Our findings propose that the down regulation of arginase-ornithine pathway expression with the reduction of arginase biosynthesis is a central mechanism and potential treatment for pulmonary fibrosis with the prevention of TL.
format Online
Article
Text
id pubmed-8114272
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81142722021-05-13 Tianlongkechuanling Inhibits Pulmonary Fibrosis Through Down-Regulation of Arginase-Ornithine Pathway Zhang, Lili Qu, Sihao Wang, Lu Wang, Chunguo Yu, Qinghe Zhang, Zhimin Diao, Yirui Zhang, Binbin Li, Yadong Shi, Yuanyuan Wang, Peng Front Pharmacol Pharmacology Background: Pulmonary Fibrosis (PF) is an interstitial lung disease characterized by excessive accumulation of extracellular matrix in the lungs, which disrupts the structure and gas exchange of the alveoli. There are only two approved therapies for PF, nintedanib (Nib) and pirfenidone. Therefore, the use of Chinese medicine for PF is attracting attention. Tianlongkechuanling (TL) is an effective Chinese formula that has been applied clinically to alleviate PF, which can enhance lung function and quality of life. Purpose: The potential effects and specific mechanisms of TL have not been fully explored, yet. In the present study, proteomics was performed to explore the therapeutic protein targets of TL on Bleomycin (BLM)-induced Pulmonary Fibrosis. Method: BLM-induced PF mice models were established. Hematoxylineosin staining and Masson staining were used to analyze histopathological changes and collagen deposition. To screen the differential proteins expression between the Control, BLM, BLM + TL and BLM + Nib (BLM + nintedanib) groups, quantitative proteomics was performed using tandem mass tag (TMT) labeling with nanoLC-MS/MS [nano liquid chromatographymass spectrometry]). Changes in the profiles of the expressed proteins were analyzed using the bioinformatics tools Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG). The protein–protein interactions (PPI) were established by STRING. Expressions of α-smooth muscle actin (α-SMA), Collagen I (Col1a1), Fibronectin (Fn1) and enzymes in arginase-ornithine pathway were detected by Western blot or RT-PCR. Result: TL treatments significantly ameliorated BLM-induced collagen deposition in lung tissues. Moreover, TL can inhibit the protein expressions of α-SMA and the mRNA expressions of Col1a1 and Fn1. Using TMT technology, we observed 253 differentially expressed proteins related to PPI networks and involved different KEGG pathways. Arginase-ornithine pathway is highly significant. The expression of arginase1 (Arg1), carbamoyltransferase (OTC), carbamoy-phosphate synthase (CPS1), argininosuccinate synthase (ASS1), ornithine aminotransferase (OAT) argininosuccinate lyase (ASL) and inducible nitric oxide synthase (iNOS) was significantly decreased after TL treatments. Conclusion: Administration of TL in BLM-induced mice resulted in decreasing pulmonary fibrosis. Our findings propose that the down regulation of arginase-ornithine pathway expression with the reduction of arginase biosynthesis is a central mechanism and potential treatment for pulmonary fibrosis with the prevention of TL. Frontiers Media S.A. 2021-04-22 /pmc/articles/PMC8114272/ /pubmed/33995084 http://dx.doi.org/10.3389/fphar.2021.661129 Text en Copyright © 2021 Zhang, Qu, Wang, Wang, Yu, Zhang, Diao, Zhang, Li, Shi and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhang, Lili
Qu, Sihao
Wang, Lu
Wang, Chunguo
Yu, Qinghe
Zhang, Zhimin
Diao, Yirui
Zhang, Binbin
Li, Yadong
Shi, Yuanyuan
Wang, Peng
Tianlongkechuanling Inhibits Pulmonary Fibrosis Through Down-Regulation of Arginase-Ornithine Pathway
title Tianlongkechuanling Inhibits Pulmonary Fibrosis Through Down-Regulation of Arginase-Ornithine Pathway
title_full Tianlongkechuanling Inhibits Pulmonary Fibrosis Through Down-Regulation of Arginase-Ornithine Pathway
title_fullStr Tianlongkechuanling Inhibits Pulmonary Fibrosis Through Down-Regulation of Arginase-Ornithine Pathway
title_full_unstemmed Tianlongkechuanling Inhibits Pulmonary Fibrosis Through Down-Regulation of Arginase-Ornithine Pathway
title_short Tianlongkechuanling Inhibits Pulmonary Fibrosis Through Down-Regulation of Arginase-Ornithine Pathway
title_sort tianlongkechuanling inhibits pulmonary fibrosis through down-regulation of arginase-ornithine pathway
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114272/
https://www.ncbi.nlm.nih.gov/pubmed/33995084
http://dx.doi.org/10.3389/fphar.2021.661129
work_keys_str_mv AT zhanglili tianlongkechuanlinginhibitspulmonaryfibrosisthroughdownregulationofarginaseornithinepathway
AT qusihao tianlongkechuanlinginhibitspulmonaryfibrosisthroughdownregulationofarginaseornithinepathway
AT wanglu tianlongkechuanlinginhibitspulmonaryfibrosisthroughdownregulationofarginaseornithinepathway
AT wangchunguo tianlongkechuanlinginhibitspulmonaryfibrosisthroughdownregulationofarginaseornithinepathway
AT yuqinghe tianlongkechuanlinginhibitspulmonaryfibrosisthroughdownregulationofarginaseornithinepathway
AT zhangzhimin tianlongkechuanlinginhibitspulmonaryfibrosisthroughdownregulationofarginaseornithinepathway
AT diaoyirui tianlongkechuanlinginhibitspulmonaryfibrosisthroughdownregulationofarginaseornithinepathway
AT zhangbinbin tianlongkechuanlinginhibitspulmonaryfibrosisthroughdownregulationofarginaseornithinepathway
AT liyadong tianlongkechuanlinginhibitspulmonaryfibrosisthroughdownregulationofarginaseornithinepathway
AT shiyuanyuan tianlongkechuanlinginhibitspulmonaryfibrosisthroughdownregulationofarginaseornithinepathway
AT wangpeng tianlongkechuanlinginhibitspulmonaryfibrosisthroughdownregulationofarginaseornithinepathway